Grant: Research Tools and Instruments
Université de Montréal
$126,522.00
Fabrication and characterization of living pulmonary heart valves using 3D (bio)printing and human induced pluripotent stem cell technologies
FY 2024-25
Summary
We propose purchasing a unique heart valve bioreactor (APTUS Bioreactors, USA, the only vendor of such a platform to the best of our knowledge). The APTUS heart valve bioreactor provides a versatile system used to test and develop heart valves under physiological conditions. This system is used for preconditioning valve scaffolds, pre-clinical testing of tissue development, durability, and hemodynamic compatibility, and testing cardiovascular implants on heart valves. Using additional accessories, the bioreactor system can be used to replace early-stage animal models or in vitro models for studying valve physiology, pathology, and patient-specific theranostics. The uniqueness of this technology will push the frontiers of 3D biofabrication of tissue-engineered heart valves, both in fundamental and applied research.
The requested instrument will uniquely support and complement the mission of our innovative research program to 1) formulate, characterize, and validate novel hydrogels/bioinks for 3D bioprinting of human pluripotent stem cell-derived tissues; and 2) develop and characterize tissue-engineered heart valves using cutting-edge 3D bioprinting and human pluripotent stem cell technologies. It also supports the vision of our program to produce and validate engineered tissues and organs for replacement.
The instrument will be installed at the Research Center of the Sainte Justine Hospital (CRCHUSJ). This will enable all interested users in the CRCHUSJ, University of Montreal, Concordia University, McGill University, Montreal General Hospital, Research Center of the University of Montreal Hospital Center, and the Greater Montreal area to have access to the instrument, which will generate significant interdisciplinary collaborative works. The instrument will be used by trainees (HQP) of the principal applicant, co-applicants, their collaborators, and users to acquire hands-on training that will provide them with the marketable skills required for jobs in their disciplines. The heart valve bioreactor, principal applicant, co-applicants, and their collaborators' laboratories will become attraction poles for highly motivated and qualified students and researchers in biomedical engineering.
By urgently acquiring this heart valve bioreactor, our innovative research program will revolutionize tissue engineering and organ bioprinting and have spectacular potential for future global leadership in tissue manufacturing and its characterizations. It will also generate social, health, and economic benefits for Canadians, including enhanced training and improved skills for HQP. The benefits of this program will be realized by technology transfer activities, intellectual property licensing, the creation of new start-up companies, and collaboration with our partners, including the National Research Council of Canada, Montreal TransMedTech Institute, Axelys, and MEDTEQ+, among others.
Program
Research Tools and Instruments
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RTI-2025-00195
Name nom
Savoji, Houman
Department département
Biomedical Engineering
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2025
Award amount
126522
Program id
RTI
Program name en
Research Tools and Instruments
Program name fr
Outils et instruments de recherche
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1602
Committee name en
Biological Systems and Functions (RTI)
Committee name fr
Systèmes et fonctions biologiques (OIR)
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Fabrication and characterization of living pulmonary heart valves using 3D (bio)printing and human induced pluripotent stem cell technologies
Keywords
heart valves; 3d bioprinting; bioreactor; bioinks; valve interstitial cells; structure-function study; hydrodynamics; tissue engineering; regenerative medicine; human induced pluripotent stem cells
Application summary
We propose purchasing a unique heart valve bioreactor (APTUS Bioreactors, USA, the only vendor of such a platform to the best of our knowledge). The APTUS heart valve bioreactor provides a versatile system used to test and develop heart valves under physiological conditions. This system is used for preconditioning valve scaffolds, pre-clinical testing of tissue development, durability, and hemodynamic compatibility, and testing cardiovascular implants on heart valves. Using additional accessories, the bioreactor system can be used to replace early-stage animal models or in vitro models for studying valve physiology, pathology, and patient-specific theranostics. The uniqueness of this technology will push the frontiers of 3D biofabrication of tissue-engineered heart valves, both in fundamental and applied research.
The requested instrument will uniquely support and complement the mission of our innovative research program to 1) formulate, characterize, and validate novel hydrogels/bioinks for 3D bioprinting of human pluripotent stem cell-derived tissues; and 2) develop and characterize tissue-engineered heart valves using cutting-edge 3D bioprinting and human pluripotent stem cell technologies. It also supports the vision of our program to produce and validate engineered tissues and organs for replacement.
The instrument will be installed at the Research Center of the Sainte Justine Hospital (CRCHUSJ). This will enable all interested users in the CRCHUSJ, University of Montreal, Concordia University, McGill University, Montreal General Hospital, Research Center of the University of Montreal Hospital Center, and the Greater Montreal area to have access to the instrument, which will generate significant interdisciplinary collaborative works. The instrument will be used by trainees (HQP) of the principal applicant, co-applicants, their collaborators, and users to acquire hands-on training that will provide them with the marketable skills required for jobs in their disciplines. The heart valve bioreactor, principal applicant, co-applicants, and their collaborators' laboratories will become attraction poles for highly motivated and qualified students and researchers in biomedical engineering.
By urgently acquiring this heart valve bioreactor, our innovative research program will revolutionize tissue engineering and organ bioprinting and have spectacular potential for future global leadership in tissue manufacturing and its characterizations. It will also generate social, health, and economic benefits for Canadians, including enhanced training and improved skills for HQP. The benefits of this program will be realized by technology transfer activities, intellectual property licensing, the creation of new start-up companies, and collaboration with our partners, including the National Research Council of Canada, Montreal TransMedTech Institute, Axelys, and MEDTEQ+, among others.